Thomas A. Waldmann, M.D.
Affiliations: | National Institutes of Health, Bethesda, MD |
Area:
Immunology and InflammationWebsite:
https://irp.nih.gov/pi/thomas-waldmannGoogle:
"Thomas A. Waldmann"Bio:
http://www.nasonline.org/member-directory/members/45743.html
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Brammer JE, Ballen K, Sokol L, et al. (2023) Effective Treatment with the Selective Cytokine Inhibitor BNZ-1 Reveals the Cytokine Dependency of T-LGL Leukemia. Blood |
| Sato N, Bamford RN, Bryant BR, et al. (2023) Accessory cells precondition naïve T cells and regulatory T cells for cytokine-mediated proliferation. Proceedings of the National Academy of Sciences of the United States of America. 120: e2217562120 |
| Miljkovic MD, Dubois S, Müller JR, et al. (2022) Interleukin-15 augments NK cell-mediated ADCC of alemtuzumab in patients with CD52+ T-cell malignancies. Blood Advances |
| Chen W, Bamford RN, Edmondson EF, et al. (2022) IL-15 and anti-PD-1 augment the efficacy of agonistic intratumoral anti-CD40 in a mouse model with multiple TRAMP-C2 tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Daenthanasanmak A, Lin Y, Zhang M, et al. (2020) Enhanced efficacy of JAK1 inhibitor with mTORC1/C2 targeting in smoldering/chronic adult T cell leukemia. Translational Oncology. 14: 100913 |
| Dubois S, Waldmann TA, Müller JR. (2020) Engagement of lymphoma T cell receptors causes accelerated growth and the secretion of an NK cell-inhibitory factor. Cellular Immunology. 357: 104213 |
| Hangasky JA, Waldmann TA, Santi DV. (2020) Interleukin 15 Pharmacokinetics and Consumption by a Dynamic Cytokine Sink. Frontiers in Immunology. 11: 1813 |
| Traba J, Waldmann TA, Anton OM. (2020) Analysis of Human Natural Killer Cell Metabolism. Journal of Visualized Experiments : Jove |
| Waldmann TA, Dubois S, Miljkovic MD, et al. (2020) IL-15 in the Combination Immunotherapy of Cancer. Frontiers in Immunology. 11: 868 |
| Conlon KC, Sportes C, Brechbiel MW, et al. (2020) Y-Daclizumab (Anti-CD25), High-Dose Carmustine, Etoposide, Cytarabine, and Melphalan Chemotherapy and Autologous Hematopoietic Stem Cell Transplant Yielded Sustained Complete Remissions in 4 Patients with Recurrent Hodgkin's Lymphoma. Cancer Biotherapy & Radiopharmaceuticals |